Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
Scipher announced positive outcomes of its retrospective trial for its test Prism used to predict clinical utility, with data predicting it could double patients’ response rate to major therapies.
Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
Alnylam has both acquired Merck & Co. subsidiary Sirna therapeutics and extended an alliance with Genzyme in order to advance its small interfering RNA (siRNA) delivery programme.
With Angiomax potentially going generic in 2015, The Medicines Company has collaborated with Alnylam over a 'pragmatic' high cholesterol drug to aid future growth.
RXi and EyeGate lift the lid on ocular delivery of RNAi therapeutics for retinal disorders as the two firm’s team up to provide a unique needle-free solution.
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.
The latest work on siRNA delivery is focused on in a special edition of Molecular Pharmaceutics, which details the techniques researchers are using to target cells and make more effective therapeutics.
Abbott Laboratories has licensed Liquidia Technologies’ PRINT nanoparticle technology for the delivery of siRNA-based therapeutics, which have the potential to improve the company’s cancer portfolio.
Novartis’ extension of its collaboration with Alnylam Therapeutics and Roche’s acquisition of gene silencing specialist Mirus Bio Corp for $125m (€78.5m) suggest that big pharma is beginning to recognize the commercial potential of RNAi-based therapeutics.
French firm Polyplus-transfection hopes that its new "sticky siRNA"
(ssiRNA) technology, which allows siRNA molecules to form more
stable structures, will revolutionize the in vivo delivery
of small interfering-RNA based...
AstraZeneca (AZ) and Roche have became the latest big pharma firms
to invest in RNA interference (RNAi), having penned separate
licensing deals with two of the industry's leading specialists in
the field.
The race to put the first cancer therapy based on RNA interference
(RNAi) technology into clinical trials has heated up with one
developer claiming it is almost ready to go.
US researchers have developed a novel delivery vehicle for siRNA,
an up-and-coming technology for switching off genes in the body
that could accelerate its use in drug development.
Bio-Rad Labs and Integrated DNA Technologies (IDT), have announced
a collaboration to develop RNA interference (RNAi) tools sets for
life science researchers.
A novel lab technique, which involves RNA interference to silence
genes in immune cells, is set to provide biology researchers
broader access to RNA interference, especially for scientists doing
research in immunology.
Scientists at Atugen, a German-based firm, have successfully used a
new RNA interference (RNAi) technology to reduce tumour growth and
spread, according to new research published.
Dharmacon and Alcon are to collaborate on the discovery of new
therapies for eye disease using RNAi technology. The specificity
and novel molecular mechanism of RNAi may allow for the development
of safer and more effective drugs...
S R Pharma have released its interim results for the first half of
2005, which show the continued consolidation of Research and
Development costs as resources were diverted to acquire contract
development services provider, Atugen.
Sigma-Aldrich has completed the acquisition of JRH Biosciences
division (JRH) for $370 million (€282 million) in cash, extending
its presence in the cell culture product sector and consolidating
its position in the burgeoning functional...
Dharmacon and Genentech have entered into a collaboration in which
RNA interference (RNAi) technology is to be used in future drug
discovery and development research. One focus of the deal is gene
silencing, a powerful and increasingly...
RNA interference specialist Alnylam Pharmaceuticals has made
progress in its collaboration with US pharma major Merck & Co,
with the latter making a $7 million milestone payment as a result.
Dharmacon has launched a range of small interfering RNA (siRNA)
transfection reagents designed specifically to enhance transfection
efficiency, a crucial procedure in initial drug target
identification to late-stage therapeutic development.
The first ever-manufacturing agreement for a drug based on small
interfering RNA emphasises the potential of this pioneering
therapeutic approach, which could be a fertile stamping ground for
contract manufacturers.
Researchers have demonstrated for the first time that physical
symptoms and neurological damage caused by an inherited
neurodegenerative disease that is similar to Huntingdon's disease
(HD) may be prevented by gene therapy.
Fisher Scientific International has swooped on two companies
providing tools for life sciences companies in a move designed to
boost its product range for research laboratories and
biopharmaceutical production.
Merck & Co has become the first drug major to make a
significant alliance in the field of RNA interference - one of the
hottest topics in drug discovery - via a deal with Alnylam
Pharmaceuticals.
In the second piece of news today on RNAi, Qiagen is to collaborate
with Intradigm on RNAi compounds for use as drug discovery tools
and potential therapeutics.
